Wells P S, Blajchman M A, Henderson P, Wells M J, Demers C, Bourque R, McAvoy A
Canadian Red Cross Society, Hamilton, Ontario, Canada.
Am J Hematol. 1994 Apr;45(4):321-4. doi: 10.1002/ajh.2830450409.
The prevalence of antithrombin (AT) deficiency in the general population has been variously estimated to be between 0.05 and 5 per 1,000 in the population; 2,491 blood donors were screened in an attempt to clarify this issue using plasma samples taken from the blood donor units. From this initial population, 122 individuals were identified as having plasma AT levels lower than 2 standard deviations below the normal mean. Twenty-two samples had evidence that thrombin had been generated during blood collection and the remaining cohort of 100 blood donors were asked to return but only 59 complied. The data obtained from these 59 were compared with that from 51 age- and sex-matched control blood donors. Both groups of subjects were assessed for previous evidence, or family history, of thrombotic events, as well as exposure to risk factors associated with the development of deep vein thrombosis (DVT). All had venous blood samples taken from which the supernatant plasma was immediately removed and quick frozen for later assaying. Only 6 of the 59 subjects with initial low AT levels had repeat AT-Xa levels below 0.80 units/ml (normal range 0.94 +/- 0.14). Upon repeating the AT-Xa determinations on new samples from these six individuals, only three were found again to be low. One was found to have a type 3 AT deficiency (an Arg47Cys substitution). The other two with a low AT level had mean functional AT-Xa levels of 0.61 and 0.71 units/ml, respectively, with correspondingly low AT:Ag levels consistent with a type 1 AT deficiency. Two of these three subjects has been in high risk situations without evidence of having developed DVT and none had evidence of venous reflux on Doppler venography. In addition, none had personal or family histories of previous thrombotic events. These present data indicate that the prevalence of AT deficiency in our blood donor population is 2 per 1,000 (95% confidence intervals: 0.7-6/1,000).
普通人群中抗凝血酶(AT)缺乏症的患病率估计各不相同,每1000人中在0.05至5之间;为了澄清这个问题,对2491名献血者进行了筛查,使用从献血单位采集的血浆样本。从最初的人群中,有122人被确定血浆AT水平低于正常均值2个标准差。22个样本有证据表明采血过程中产生了凝血酶,其余100名献血者被要求回访,但只有59人前来。将这59人获得的数据与51名年龄和性别匹配的对照献血者的数据进行比较。两组受试者都被评估是否有血栓形成事件的既往证据或家族史,以及是否接触过与深静脉血栓形成(DVT)相关的危险因素。所有人都采集了静脉血样本,立即分离出上清血浆并速冻以备后续检测。最初AT水平较低的59名受试者中,只有6人的重复AT-Xa水平低于0.80单位/毫升(正常范围0.94±0.14)。对这6个人的新样本重复进行AT-Xa测定后,只有3人再次被发现水平较低。其中1人被发现患有3型AT缺乏症(Arg47Cys替代)。另外两名AT水平较低的人,其平均功能性AT-Xa水平分别为0.61和0.71单位/毫升,相应的AT:Ag水平较低,符合1型AT缺乏症。这三名受试者中有两名处于高风险情况,但没有发生DVT的证据,且在多普勒静脉造影中均没有静脉反流的证据。此外,没有人有个人或家族既往血栓形成事件的病史。目前的数据表明,我们献血人群中AT缺乏症的患病率为每1000人中有2人(95%置信区间:0.7 - 6/1000)。